In contrast, another study demonstrated that hetIL-15 administration alters the cytokine and cellular landscape within the tumor, enhancing T cell and cDC1 entry into the tumor and thereby increasing the success rate of immunotherapeutic interventions [64]. This evidence concerns the gene MPPE1 and neoplasm.